证券代码：688139 证券简称：海尔生物 公告编号：2025-036 青岛海尔生物医疗股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 法律责任。 本次回购股份符合法律法规的规定及公司回购股份方案。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 重要内容提示： 青岛海尔生物医疗股份有限公司（以下简称"公司"）于 2025 年 1 月 13 日召 开第三届董事会第四次会议，审议通过了《关于以集中竞价交易方式回购公司股 份方案的议案》（以下简称"本次回购方案"），同意公司以自有资金通过上海证券 交易所股票交易系统以集中竞价交易方式回购公司已发行的部分人民币普通股（A 股）。回购的股份将在未来适宜时机全部用于员工持股计划或股权激励，回购价格 不超过 50 元/股（含），回 ...

Investment Rating - The report maintains a "Recommendation" rating for Haier Biomedical (688139) [1] Core Views - The company reported Q1 2025 revenue of 689 million yuan, a slight increase of 0.30% year-on-year, while net profit attributable to shareholders decreased by 19.88% to 110 million yuan [1] - Non-storage new industries continue to maintain high growth, with overseas business returning to stable growth [1] - The company expects net profit attributable to shareholders for 2025-2027 to be 440 million, 540 million, and 640 million yuan, with year-on-year growth rates of 20.6%, 23.1%, and 18.3% respectively [7] Financial Performance Summary - Total revenue forecast for 2024A is 2,284 million yuan, with expected growth rates of 0.1% in 2024, 15.2% in 2025, 16.4% in 2026, and 13.2% in 2027 [3] - The net profit attributable to shareholders is projected to decline by 9.7% in 2024, followed by increases of 20.6%, 23.1%, and 18.3% in the subsequent years [3] - The earnings per share (EPS) is expected to rise from 1.15 yuan in 2024 to 2.02 yuan in 2027 [3] Business Segment Performance - The low-temperature storage business showed a narrowing decline, with a return to positive growth in Q4 2024 and continued improvement in Q1 2025 [7] - Non-storage new industries accounted for 44% of revenue in Q1 2025, with a year-on-year growth of 13.92% and a quarter-on-quarter growth of 27.35% [7] - Domestic revenue in Q1 2025 was 482 million yuan, a decrease of 3.35% year-on-year but an increase of 54.98% quarter-on-quarter [7] Investment Recommendations - The report maintains the profit forecast unchanged, with a target price of approximately 42 yuan based on a DCF model, corresponding to a total valuation of 13.3 billion yuan [7] - The company is expected to achieve a price-to-earnings (PE) ratio of 23, 19, and 16 for the years 2025, 2026, and 2027 respectively [3]

Core Viewpoint - Haier Biomedical's Q1 revenue reached 688.99 million, a year-on-year increase of 0.30%, indicating a return to normal business development despite challenges in the market [2][3]. Revenue Summary - Total revenue for Q1 2025 was 688.99 million, compared to 686.91 million in the same period last year, reflecting a growth of 0.30% [3]. - Net profit attributable to shareholders decreased by 19.88% to 110.26 million, while the net profit after deducting non-recurring gains and losses fell by 25.38% to 99.17 million [3]. - Operating cash flow decreased significantly by 51.79% to 37.22 million [3]. - Basic and diluted earnings per share both dropped by 20.45% to 0.35 yuan [3]. Business Segment Performance - The Life Sciences segment generated revenue of 354 million, up 1.06% year-on-year and 53.28% quarter-on-quarter [3]. - The Medical Innovation segment reported revenue of 332 million, down 0.61% year-on-year but up 24.26% quarter-on-quarter [3]. Growth Drivers 1. Non-storage new industries maintained high growth, with revenue share at 44%, increasing by 13.92% year-on-year and 27.35% quarter-on-quarter, driven by growth in plasma consumables, medication automation, laboratory consumables, and instruments [4]. 2. Domestic scenario solutions continued to expand, with domestic market revenue at 482 million, down 3.35% year-on-year but up 54.98% quarter-on-quarter, enhancing brand strength and competitiveness [4]. 3. The overseas market showed signs of recovery with revenue of 204 million, a year-on-year increase of 9.88% and a quarter-on-quarter increase of 8.99%, reversing the decline seen in 2024 [4]. Future Industry Layout - Haier Biomedical is actively expanding into future industries such as CGT and blood management, launching an intelligent fully automated cell culture workstation and enhancing blood supply efficiency through AI and smart blood management systems [5].

Financial Overview - The company achieved total revenue of 689 million yuan in Q1 2025, a year-on-year increase of 0.3% [1] - The net profit attributable to the parent company was 110 million yuan, a year-on-year decrease of 19.88% [1] - The net profit excluding non-recurring items was 99.17 million yuan, a year-on-year decrease of 25.38%, indicating a decline in profitability despite slight revenue growth [1] Profit and Cost Analysis - The gross profit margin was 48.35%, an increase of 1.76 percentage points year-on-year, reflecting effective cost control [2] - The net profit margin was 16.86%, a year-on-year decrease of 18.33 percentage points, suggesting that other factors negatively impacted final profits despite improved gross margins [2] Expense Control - Total selling, administrative, and financial expenses reached 132 million yuan, accounting for 19.16% of revenue, which is a 38.24% increase compared to the same period last year, indicating pressure on expense control [3] Cash Flow and Assets Liabilities - The operating cash flow per share was 0.12 yuan, a year-on-year decrease of 51.79%, reflecting a deterioration in cash flow from operating activities [4] - Monetary funds decreased from 1.32 billion yuan to 831 million yuan, a decline of 37.02%, further highlighting cash flow pressures [4] Accounts Receivable and Debt Repayment Ability - As of the end of the reporting period, accounts receivable amounted to 432 million yuan, a year-on-year increase of 29.04%, with accounts receivable accounting for 117.8% of the latest annual net profit, which may adversely affect future cash flow [5] - Despite this, the company's cash assets remain in a healthy state [5] Business Model and Future Development - The company's performance relies heavily on research and marketing efforts, with cumulative financing of 1.231 billion yuan and cumulative dividends of 643 million yuan over the past six years, resulting in a dividend-to-financing ratio of 0.52 [6] - Moving forward, the company needs to focus more on the recovery of accounts receivable and improvement of cash flow to ensure sustainable development [6]

证券代码：688139 证券简称：海尔生物 公告编号：2025-034 青岛海尔生物医疗股份有限公司 关于注销部分募集资金专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、募集资金基本情况 经上海证券交易所科创板股票上市委员会 2019 年 7 月 30 日审核同意，并经 中国证券监督管理委员会 2019 年 9 月 20 日下发《关于同意青岛海尔生物医疗股 份有限公司首次公开发行股票注册的批复》（证监许可[2019]1742 号）核准， 同意青岛海尔生物医疗股份有限公司（以下简称"公司"、"本公司"或"海尔 生物"）公开发行人民币普通股不超过 79,267,940 股，每股发行价格为人民币 15.53 元，募集资金总额为人民币 1,231,031,108.20 元，实际到账金额人民币 1,161,576,074.14 元，包括尚未划转的其他发行费用。上述募集资金于 2019 年 10 月 22 日到位，并经安永华明会计师事务所（特殊普通合伙）审验并出具了安 永华明（2019）验字第 61433766_J0 ...

证券代码：688139 证券简称：海尔生物 公告编号：2025-033 青岛海尔生物医疗股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法 承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 4 月 29 日 （二） 股东大会召开的地点：盈康一生大厦 15 层会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 105 | | --- | --- | | 普通股股东人数 | 105 | | 2、出席会议的股东所持有的表决权数量 | 182,765,940 | | 普通股股东所持有表决权数量 | 182,765,940 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 58.2830 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 58.2830 | （四） 表决方式是否符 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 688,989,400.70, a year-on-year increase of 0.30% and a quarter-on-quarter increase of 37.30%[3]. - Net profit attributable to shareholders decreased by 19.88% year-on-year to CNY 110,258,240.35, while the net profit excluding non-recurring gains and losses fell by 25.38% to CNY 99,168,300.25[3]. - Total revenue for Q1 2025 reached ¥688,989,400.70, a slight increase from ¥686,909,061.52 in Q1 2024, representing a growth of approximately 0.31%[21]. - Net profit for Q1 2025 was ¥116,197,969.19, compared to ¥141,852,238.97 in Q1 2024, reflecting a decrease of approximately 18.1%[22]. - The total comprehensive income for Q1 2025 was ¥116,655,247.96, down from ¥141,864,993.51 in Q1 2024, reflecting a decrease of about 17.73%[22]. - Basic and diluted earnings per share for Q1 2025 were both CNY 0.35, down from CNY 0.44 in Q1 2024, indicating a decrease of approximately 20.45% year-over-year[23]. Cash Flow - The net cash flow from operating activities dropped significantly by 51.79% to CNY 37,219,201.54 compared to the previous year[3][13]. - Cash inflow from operating activities for Q1 2025 was CNY 580,704,504.07, compared to CNY 560,317,919.65 in Q1 2024, reflecting an increase of about 3.46%[24]. - Net cash flow from operating activities decreased to CNY 37,219,201.54 in Q1 2025, down 51.74% from CNY 77,204,996.82 in Q1 2024[24]. - The company reported a total cash outflow from operating activities of CNY 543,485,302.53 in Q1 2025, compared to CNY 483,112,922.83 in Q1 2024, reflecting an increase of about 12.49%[24]. - Cash inflow from investment activities for Q1 2025 was CNY 1,109,537,955.23, significantly higher than CNY 384,384,067.11 in Q1 2024, marking an increase of approximately 188.06%[25]. - Net cash flow from investment activities improved to CNY 82,434,530.50 in Q1 2025, compared to a negative CNY 7,529,404.95 in Q1 2024[25]. - Cash inflow from financing activities totaled CNY 194,362,611.12 in Q1 2025, a substantial increase from CNY 5,170,000.00 in Q1 2024[25]. - The net increase in cash and cash equivalents for Q1 2025 was CNY 102,689,591.57, compared to CNY 50,425,150.14 in Q1 2024, indicating a growth of approximately 103.67%[25]. - The ending balance of cash and cash equivalents as of Q1 2025 was CNY 637,393,622.25, down from CNY 1,307,071,714.34 in Q1 2024[25]. Market Performance - The life sciences segment generated revenue of CNY 354 million, up 1.06% year-on-year and 53.28% quarter-on-quarter[5]. - Domestic market revenue was CNY 482 million, down 3.35% year-on-year but up 54.98% quarter-on-quarter, indicating resilience in a challenging market[6]. - Overseas market revenue reached CNY 204 million, showing a year-on-year growth of 9.88% and a quarter-on-quarter increase of 8.99%[7]. - The market share of the company's biological safety cabinet products has risen to the second brand in the domestic market during Q1 2025[7]. Research and Development - Research and development expenses totaled CNY 80,452,189.16, representing 11.68% of operating revenue, an increase of 0.43 percentage points year-on-year[4]. - Research and development expenses for Q1 2025 were ¥80,452,189.16, compared to ¥77,257,984.27 in Q1 2024, indicating a growth of about 2.85%[21]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,793[15]. - The largest shareholder, Qingdao Haier Biomedical Co., Ltd., holds 100,591,463 shares, accounting for 31.64% of the total shares[15]. - The second largest shareholder, Qingdao Haizhi Huiying Equity Investment Management Co., Ltd., holds 32,103,659 shares, representing 10.10% of the total shares[15]. - The company has no changes in the top 10 shareholders due to securities lending activities[17]. Assets and Liabilities - Total current assets as of March 31, 2025, amount to ¥2,314,000,000, a decrease from ¥2,400,000,000 as of December 31, 2024[18]. - Cash and cash equivalents decreased to ¥831,055,160.95 from ¥901,227,075.69[18]. - Accounts receivable increased to ¥431,897,441.94 from ¥323,845,820.79, indicating a growth of approximately 33.5%[18]. - Inventory decreased to ¥303,739,515.42 from ¥334,744,974.95, a decline of about 9.3%[18]. - The company's total assets amounted to ¥5,830,440,601.44, slightly up from ¥5,787,468,795.01 in the previous year[21]. - Total liabilities decreased to ¥1,121,639,324.69 from ¥1,169,332,762.22, showing a reduction of about 4.08%[20]. - The equity attributable to shareholders increased to ¥4,456,255,374.10 from ¥4,371,550,511.01, marking an increase of approximately 1.94%[20]. Operational Conditions - The company has not reported any significant changes in operational conditions during the reporting period[17]. - The company has not disclosed any new strategies or product developments in the current reporting period[17]. - The company did not report any net profit from the merged entity prior to the merger, with previous periods also showing zero net profit[23].

北京市金杜（青岛）律师事务所 关于青岛海尔生物医疗股份有限公司 2024 年年度股东大会之 法律意见书 致：青岛海尔生物医疗股份有限公司 北京市金杜（青岛）律师事务所（以下简称本所）接受青岛海尔生物医疗 股份有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简 称《证券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监 督管理委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民 共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特 别行政区、中国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、 规章、规范性文件和现行有效的《青岛海尔生物医疗股份有限公司章程》（以下 简称《公司章程》）的有关规定，指派律师出席了公司于 2025 年 4 月 29 日召 开的 2024 年年度股东大会（以下简称本次股东大会），并就本次股东大会相关 事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限 于： 1. 经公司 2024 年第一次临时股东大会审议通过的《公司章程》； 2. 公司 2025 年 3 月 29 日刊登于巨潮资讯 ...

海尔生物公告，2025年第一季度营业收入6.89亿元，同比增长0.30%。净利润1.1亿元，同比下降 19.88%。 ...